Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.

Christopher Sweeney,Andrew J. Martin,Robert Zielinski,Alastair Thomson,Thean Hsiang Tan,Shahneen Sandhu,M. Neil Reaume,David William Pook,Francis Parnis,Scott North,Ray McDermott,John McCaffrey,Gavin Marx,Nicola Jane Lawrence,Lisa G. Horvath,Mark Frydenberg,Simon Chowdhury,Kim N. Chi,Martin R. Stockler,Ian D. Davis

Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.

2019

LBA2Background: Testosterone suppression (TS) is the backbone of treatment for mHSPC. OS is improved by the addition of early docetaxel (DOC) or abiraterone to TS. ENZAMET assessed the effects of e...

Keywords:

Randomized controlled trial
Physical therapy
Oncology
Hormone sensitive prostate cancer
Internal medicine
Enzalutamide
Medicine
standard of care
Docetaxel
Testosterone
overall survival
cooperative group

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations